FDA approves Verona Pharma's therapy for 'smoker's lungs'
26/06/2024 22:00
June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. (Reporting by Pratik Jain and Sruthi Narasimha Chari in Bengaluru; Editing by Pooja Desai) ((SruthiNarasimha.Chari@thomsonreuters.com))
Recent news on Verona Pharma
See all newsBrief: Acquisition Of Verona By Msd Approved By The High Court Of Justice Of England And Wales
Brief: Shareholders Of Verona Pharma Approve Proposed Acquisition By Merck
US corporate debt market returns in force after market holiday
Merck to cut jobs and costs as demand for Gardasil in China remains weak (updated)
Merck to cut jobs and costs as demand for Gardasil in China remains weak